Compare RELL & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | LCTX |
|---|---|---|
| Founded | 1947 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.1M | 301.7M |
| IPO Year | 2004 | 1996 |
| Metric | RELL | LCTX |
|---|---|---|
| Price | $17.71 | $1.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 156.3K | ★ 816.9K |
| Earning Date | 04-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $228,564,000.00 | $14,556,000.00 |
| Revenue This Year | $6.32 | $109.40 |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | 9.41 | ★ 53.24 |
| 52 Week Low | $9.37 | $1.00 |
| 52 Week High | $23.15 | $2.09 |
| Indicator | RELL | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 50.78 |
| Support Level | $16.45 | $1.02 |
| Resistance Level | $17.94 | $1.18 |
| Average True Range (ATR) | 0.78 | 0.05 |
| MACD | -0.09 | 0.00 |
| Stochastic Oscillator | 47.75 | 51.72 |
Richardson Electronics Ltd is a world-wide manufacturer of engineered solutions, green energy products, power grid and microwave tubes, and related consumables; power conversion and RF and microwave components including green energy solutions; tubes for diagnostic imaging equipment; and customized display solutions. It serve customers in alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific, and semiconductor markets. Its products and services include design-in support, systems integration, prototype design and manufacturing, testing, logistics, etc. Its segments are Power and Microwave Technologies (PMT), Green Energy Solutions (GES), and Canvys. Majority of Sales is from PMT. Majority of sales is from North America.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.